title: Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.
abstract: BACKGROUND
  Recently, two infliximab biosimilar monoclonal antibodies (mAb) have been approved by the European Medical Agency for all immune-mediated inflammatory diseases (IMID), including inflammatory bowel disease (IBD). Current knowledge regarding biosimilars among gastroenterologists and in particular among IBD specialists is unknown. Therefore we developed a web survey to evaluate the awareness of biosimilar mAb among IBD specialists and their readiness to use these therapies.
  
  
  METHODS
  A 15-question multiple choice anonymous web survey was conducted with the logistic support of ECCO, with questions covering the most relevant aspects on biosimilars. Randomly selected ECCO members were invited by e-mail to participate. A descriptive analysis of responses was performed and analyzed.
authors.affiliation: IBD Center, Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy. Electronic address: sdanese@hotmail.com.
authors.forename: Silvio
authors.initials: S
authors.lastname: Danese
authors.affiliation: IBD Center, Gastroenterology, Humanitas Research Hospital, Rozzano, Milan, Italy.
authors.forename: Gionata
authors.initials: G
authors.lastname: Fiorino
authors.affiliation: IBD Center, Gastroenterology, La Source-Beaulieu, Lausanne, Switzerland.
authors.forename: Pierre
authors.initials: P
authors.lastname: Michetti
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001291:Attitude of Health Personnel; D059451:Biosimilar Pharmaceuticals / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D003424:Crohn Disease / Q000188:drug therapy*; D017277:Drug Approval; D057915:Drug Substitution; D005060:Europe; D005762:Gastroenterology; D019538:Health Care Surveys; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D000069285:Infliximab
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D059451:Biosimilar Pharmaceuticals; D000069285:Infliximab
keywords: Biosimilar; ECCO; Inflammatory bowel disease; Monoclonal